Journal
FUTURE ONCOLOGY
Volume 14, Issue 29, Pages 3001-3013Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0401
Keywords
AAT; AATZ; DNAJB11; ERdj3; HCC
Categories
Funding
- National Natural Science Foundation of PR China [81370580]
- Innovation project of yibin science and technology bureau [2017ZSF007-10]
Ask authors/readers for more resources
Aim: The co-chaperone ERdj3/DNAJB11 is involved in the endoplasmic reticulum stress response observed in cancer cells. We hypothesized that ERdj3 functions as a hepatocellular carcinoma (HCC) oncogene by inhibiting AATZ degradation. Materials & methods: ERdj3 and AATZ expressions were analyzed in 84 HCC patients. Cell proliferation, epithelial-mesenchymal transition marker expression, migration and invasiveness were assessed in HepG2 and Huh-7 cells. A murine xenograft tumor model was constructed. Results: ERdj3 is upregulated in HCC tumors and cell lines. Tumor ERdj3 levels are positively associated with cirrhosis, enhanced HCC status, inferior survival outcomes and AATZ levels. ERdj3 suppresses AATZ degradation. ERdj3 overexpression enhances proliferation, epithelial-mesenchymal transition marker expression, migration, invasiveness and xenograft tumor growth in an AATZ-dependent manner. Conclusion: ERdj3 enhances HCC progression through suppressing AATZ degradation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available